We have used the yeast two-hybrid system to isolate cDNAs encoding proteins that specifically interact with the 42-aa -amyloid peptide (A), a major constituent of senile plaques in Alzheimer's disease. The carboxy terminus of ␣ 2 -macroglobulin (␣2M), a proteinase inhibitor released in response to inf lammatory stimuli, was identified as a strong and specific interactor of A, utilizing this system. Direct evidence for this interaction was obtained by co-immunoprecipitation of ␣2M with A from the yeast cell, and by formation of SDS-resistant A complexes in polyacrylamide gels by using synthetic A and purified ␣2M. The association of A with ␣2M and various purified amyloid binding proteins was assessed by employing a method measuring proteinprotein interactions in liquid phase. The dissociation constant by this technique for the ␣2M-A association using labeled purified proteins was measured (K d ؍ 350 nM). Electron microscopy showed that a 1:8 ratio of ␣2M to A prevented fibril formation in solution; the same ratio to A of another acute phase protein, ␣ 1 -antichymotrypsin, was not active in preventing fibril formation in vitro. These results were corroborated by data obtained from an in vitro aggregation assay employing Thiof lavine T. The interaction of ␣2M with A suggests new pathway(s) for the clearance of the soluble amyloid peptide.Senile plaques in the brain and cerebral blood vessels of patients with Alzheimer's disease are composed primarily of the aggregated form of A (1, 2). The A peptide is derived post-translationally by proteolytic activity from a larger amyloid precursor protein (3-10). The mechanism for A clearance or for its deposition is not known. Two proteinase inhibitors, ␣ 2 -macroglobulin (␣2M) and ␣ 1 -antichymotrypsin (␣1ACT), have been identified as being associated with senile plaques (11,12,13). ␣2M is capable of binding to and blocking the proteolytic activity of most proteinases before rapid clearance of these ␣2M -proteinase complexes by the low density lipoprotein receptor-related protein (LRP). Internalization and degradation of ␣1ACT-proteinase complexes are mediated by the serpin-enzyme complex receptor. Significantly increased levels of both ␣2M and ␣1ACT are often found in localized areas of inflammation (14,15,16). The full range of biological activities of ␣2M and ␣1ACT still remains to be defined.In an effort to identify proteins that interact in vivo with A and therefore might play a role in its clearance or deposition, we screened a HeLa library using the yeast two-hybrid system (17-21). One of the proteins determined to have a strong and specific interaction with A was ␣2M. To examine the possible role of this interaction in neurotoxic amyloid fibril formation, we investigated the following: (i) the in vivo binding of A to ␣2M in the yeast cell; (ii) the in vitro binding affinity of A to ␣2M compared with that of A to other amyloid-binding proteins; and (iii) the effect of ␣2M, ␣1ACT, and apolipoprotein (apo) J on fibril formation.
EXPERIMENTA...
Macrophage migration inhibitory factor (MIF) is a cytokine that was first described as an inhibitor of the random migration of monocytes and macrophages and has since been proposed to have a number of immune and catalytic functions. One of the functions assigned to MIF is that of a tautomerase that interconverts the enol and keto forms of phenylpyruvate and (p-hydroxyphenyl)pyruvate and converts D-dopachrome, a stereoisomer of naturally occurring L-dopachrome, to 5,6-dihydroxyindole-2-carboxylic acid. The physiological significance of the MIF enzymatic activity is unclear. The three-dimensional structure of MIF is strikingly similar to that of two microbial enzymes (4-oxalocrotonate tautomerase and 5-carboxymethyl-2-hydroxymuconate isomerase) that otherwise share little sequence identity with MIF. MIF and these two enzymes have an invariant N-terminal proline that serves as a catalytic base. Here we report a new biological function for MIF, as an inhibitor of monocyte chemoattractant protein 1- (MCP-1-) induced chemotaxis of human peripheral blood monocytes. We find that MIF inhibition of chemotaxis does not occur at the level of the CC chemokine receptor for MCP-1, CCR2, since MIF does not alter the binding of (125)I-MCP-1 to monocytes. The role of MIF enzymatic activity in inhibition of monocyte chemotaxis and random migration was studied with two MIF mutants in which the N-terminal proline was replaced with either a serine or a phenylalanine. Both mutants remain capable of inhibiting monocyte chemotaxis and random migration despite significantly reduced or no phenylpyruvate tautomerase activity. These data suggest that this enzymatic activity of MIF does not play a role in its migration inhibiting properties.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.